RT Journal Article
SR Electronic
T1 A Phase 2 Multicenter Study of Irinotecan and Cisplatinum as Neoadjuvant Treatment in Patients With Locally Advanced Cervical Cancer
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 1569
OP 1575
DO 10.1111/IGC.0b013e3181cc71f7
VO 20
IS 9
A1 Francesco Raspagliesi
A1 Antonino Ditto
A1 Luigi Selvaggi
A1 Luigi Frigerio
A1 Mauro Melpignano
A1 Giovanni Scambia
A1 Chiara Apolloni
A1 Paolo Scollo
A1 Sandro Pignata
A1 Pierluigi Benedetti Panici
YR 2010
UL http://ijgc.bmj.com/content/20/9/1569.abstract
AB Hypothesis: To evaluate efficacy and safety of a neoadjuvant treatment with irinotecan and cisplatin [cis-diamminedichloroplatinum(II); CDDP] in patients with locally advanced cervical cancer.Methods: A phase 2 study was conducted at 13 centers located in Italy. Eighty-seven were enrolled between 2000 and 2003. Patients received irinotecan 175 mg/m2 on day 1 every 3 weeks followed by CDDP 80 mg/m2. Each patient was to receive 3 cycles of treatment. Tumor response was to be evaluated by magnetic resonance imaging 3 weeks after the end of the third cycle. At the end of therapy, all patients were to be examined for radical surgery.Results: Of 71 patients included in the primary analysis, 9 (12.7%) showed a complete response; and 43 (60.6%), a partial response for an overall response rate of 73.2% (95% confidence interval [CI], 61.4%-83.1%). Complete pathological responses were observed in 13.6% of the patients (95% CI, 7.0%-23.0%). Overall survival rate at 4 years was 87.0% (95% CI, 79.5%-94.5%).There were no study-related deaths. Most common adverse events were alopecia in 76 patients (87.4%) and gastrointestinal disorders in 79 patients (90.8%). Serious adverse events were vomiting in 18 patients (20.7%), nausea in 14 (16.1%), diarrhea in 8 (9.2%), and neutropenia in 50 (57.5%). A total of 3 patients (3.4%) were discontinued from the study owing to the occurrence of 1 or more serious adverse event.Conclusions: Irinotecan and CDDP as neoadjuvant chemotherapy in locally advanced cervical cancer showed a promising response rate. These data warrant confirmation with a phase 3 study.